Pharmaceuticals
July 1, 2025
Mateus Araújo Da Luz, H. Guedes, Antônio B. M. Bisneto et al.
5 citations
A review of 74 articles on Psilocybe mushrooms found that 66 reported psilocybin or psilocin, confirming psychoactivity, while 4 demonstrated antimicrobial and antioxidant activities of whole extracts. Across the genus, 37 chemical compounds were identified, 23 of which are alkaloids. Only alkaloids, terpenoids, and phenolic compounds were found, totaling just 36 compounds over 67 years of study. Most research focused on tryptamine alkaloids responsible for psychoactivity, with no studies examining isolated compounds against specific pathological factors except for whole-extract larvicidal, antimicrobial, and antioxidant potential. The authors suggest that future work should isolate new compounds and evaluate alternative biological activities.
ACS Omega
September 16, 2025
Lucas Cordeiro de Oliveira, Taynah Pereira Galdino, Marcelo Da Silva Pedro et al.
1 citation
N,N-Dimethyltryptamine (DMT), a plant-derived alkaloid, shows therapeutic potential for mental health disorders. An efficient method was established to extract, isolate, and characterize DMT from Mimosa tenuiflora, comparing root bark and stem bark. The stem bark method (sample 2C) yielded 3.45% pure DMT (0.172 g from 5.0003 g powder) and a robust phytochemical profile with alkaloids, tannins, and flavonoids. Characterization confirmed DMT identity via FTIR, HPLC-DAD (retention time 11.81 min), and GC-MS (retention time 16.4 min, 88% spectral similarity). Thermogravimetric analysis showed thermal stability up to 135 °C. Cellular viability exceeded 85% at therapeutic concentrations, with reduction only at 100 μg/mL (53 ± 21%), possibly due to overexposure. Sample 2C is a promising candidate for standardized DMT pharmaceutical formulations.
ACS Omega
September 15, 2025
Taynah Pereira Galdino, Antônio Braz de Medeiros Bisneto, Marcelo Da Silva Pedro et al.
1 citation
An active pharmaceutical ingredient (API) extracted from Psilocybe mushrooms yielded approximately 20% of target compounds, with psilocybin and psilocin contents of 3.26% and 0.34%, respectively. The API showed high purity, stability, solubility in polar solvents, low toxicity, and compliance with limits for heavy metals and microbes. It is compatible with polymeric matrices for controlled release. The work demonstrates the feasibility of a standardized psilocybin-based API for treating mental disorders.